OncoMatch/Clinical Trials/NCT07374848
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Is NCT07374848 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ZL-6201 for solid tumors.
Treatment: ZL-6201 — The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: topoisomerase inhibitor antibody-drug conjugate
Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate
Lab requirements
Blood counts
adequate organ and marrow function as listed per protocol
Kidney function
adequate organ and marrow function as listed per protocol
Liver function
adequate organ and marrow function as listed per protocol
Cardiac function
impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment [excluded]
Adequate organ and marrow function as listed per protocol; impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Zai Lab Site 02026 · Sarasota, Florida
- Zai Lab Site 02006 · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify